# Biogenosis

> Biogenosis is a VC fund in Liège backing Therapeutics, Biotechnology and Pharmaceutical. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Liège, Belgium
- Total investments: 1
- Last investment: Feb 2021
- Lead investor: 0%
- Last updated: Aug 2026

Biogenosis is a biotechnology company.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 1 | 100% |
| Biotechnology | 1 | 100% |
| Pharmaceutical | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Imcyse | Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of severe chronic autoimmune diseases. The company’s unique technology platform allows it to locally target immune cells involved in the destruction of the diseased organ. This platform is based on theadministration of Imotopes™, which are specifically modified peptides, allowing for the generation of cytolytic CD4 T-cells, that specifically eliminate antigen-presenting cells and autoantigen specific lymphocytes. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to potentially cure patients without impairing immune defense. The company has established proof of concept in several indications and has completed its first clinical trial in type 1 diabetes with promising results. Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes™ for the treatment of several autoimmune diseases. | $25.7M | Series B | Feb 17, 2021 |  |

1 of 1 investments shown.

## Co-investors
- [Epimède SA](https://shizune.co/investors/profile/epim%C3%A8de-sa) — VC Fund, 1 deal together
- [Meusinvest (Noshaq)](https://shizune.co/investors/profile/meusinvest) — VC Fund, 1 deal together
- [Pfizer](https://shizune.co/investors/profile/pfizer) — VC Fund, 1 deal together
- [SFPI-FPIM](https://shizune.co/investors/profile/sfpi-fpim) — VC Fund, 1 deal together
- [S.R.I.W.](https://shizune.co/investors/profile/s-r-i-w) — VC Fund, 1 deal together
- [KU Leuven](https://shizune.co/investors/profile/university-of-leuven) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Biogenosis invest in?

Biogenosis invests primarily in Therapeutics, Biotechnology and Pharmaceutical startups, most often at Series B stage. Most of the 1 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Biogenosis last invest?

The most recent investment recorded for Biogenosis closed in Feb 2021. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co